A Fortune 500 company, in conjunction with IBM Watson Health, conducted an economic evaluation to test whether our flagship digital therapeutic for insomnia, Sleepio, would lower health care costs for their employees.

Individuals who used Sleepio had 28% lower annualized total healthcare costs compared to those who did not use Sleepio — demonstrating $1,677 lower health care costs per employee that used Sleepio.

A peek inside:

Read the white paper

Share article

Here’s our latest

Patients initiating pharmacotherapy are generally not receiving guideline-recommended care for insomnia and anxiety

While benzodiazepine and hypnotic medications are generally not indicated as first-line treatments for insomnia and anxiety, an alarming number of…


The impact of good mental health in the retail industry

This report presents all the evidence you’ll need to make the business case for investing in employee mental health.


The impact and value of mental health initiatives by industry sector

Our latest report gives you all the evidence you need to make the case for further investment in employee mental…


BigHealth Logo

Our mission is to help millions back to good mental health with evidence-based digital therapeutics for the most prevalent mental health conditions. We’re charting the future of digital medicine by providing an inclusive, scalable, and affordable approach based on industry-leading peer-reviewed research and randomized controlled trials. From member engagement to billing via pharmacy benefit managers, we simplify adoption for both payers and patients, improving access to mental health care.

Sign up for expert advice from the Big Health team

Leave a Reply

Your email address will not be published. Required fields are marked *